Fundamental Analysis of ANAVEX LIFE SCIENCES CORP(NASDAQ:AVXL) stock

Fundamental Rating

Overall AVXL gets a fundamental rating of 3 out of 10. We evaluated AVXL against 588 industry peers in the Biotechnology industry. While AVXL has a great health rating, there are worries on its profitability. AVXL has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

AVXL had negative earnings in the past year.

In the past year AVXL has reported a negative cash flow from operations.

AVXL had negative earnings in each of the past 5 years.

In the past 5 years AVXL always reported negative operating cash flow.

1.2 Ratios

AVXL has a better Return On Assets (-29.15%) than 73.50% of its industry peers.

The Return On Equity of AVXL (-31.83%) is better than 80.17% of its industry peers.

		Industry Rank	Sector Rank
ROA	-29.15%
ROE	-31.83%
ROIC	N/A

ROA(3y)-28.55%

ROA(5y)-53.15%

ROE(3y)-30.76%

ROE(5y)-63.68%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AVXL so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for AVXL has been increased compared to 1 year ago.

The number of shares outstanding for AVXL has been increased compared to 5 years ago.

AVXL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 12.08 indicates that AVXL is not in any danger for bankruptcy at the moment.

AVXL has a Altman-Z score of 12.08. This is amongst the best in the industry. AVXL outperforms 88.38% of its industry peers.

AVXL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	12.08

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 11.85 indicates that AVXL has no problem at all paying its short term obligations.

AVXL has a better Current ratio (11.85) than 84.10% of its industry peers.

AVXL has a Quick Ratio of 11.85. This indicates that AVXL is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 11.85, AVXL belongs to the top of the industry, outperforming 84.10% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	11.85
Quick Ratio	11.85

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

AVXL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.92%, which is quite good.

EPS 1Y (TTM)16.92%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q35.29%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

AVXL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.45% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y18.4%

EPS Next 2Y-4.31%

EPS Next 3Y12.45%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

AVXL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AVXL. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as AVXL's earnings are expected to grow with 12.45% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-4.31%

EPS Next 3Y12.45%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for AVXL!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ANAVEX LIFE SCIENCES CORP

NASDAQ:AVXL (4/19/2024, 7:00:00 PM)

After market: 3.78 0 (0%)

3.78

-0.02 (-0.53%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap310.38M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-29.15%
ROE	-31.83%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	11.85
Quick Ratio	11.85
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)16.92%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y18.4%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ANAVEX LIFE SCIENCES CORP (AVXL)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens